BGPT: Author Review: Keshav K. Singh

Explore by Goal

Quick Explanation Copied

Keshav K. Singh — scientific strength (from provided dataset only): the corpus you shared shows a consistent focus on mitochondria in cancer/aging/skin, including mechanistic cell/mouse work and mitochondria–nucleus retrograde signaling, but with notable heterogeneity in study types and (where applicable) narrative-review limitations and translational gaps.

Long Explanation

Author Review: Keshav K. Singh (evidence-limited to provided records)

Date context: March 23, 2026.
Scope: I only evaluate what is explicitly included in your provided dataset (including 4 full-text/metadata-like records with DOIs + extracted evidence summaries). Where citation evidence is missing (e.g., OpenAlex timeout for author metrics), I do not assert additional facts.

How to read this figure

The bars use only the numeric paper scoring fields included in your dataset (not independent journal metrics). For example: the skin narrative review is scored 8 (quality), the mtDNA depletion rescue paper is scored 8 (quality), the miR-663 mechanistic paper is scored 9 (quality), and the prostate aconitase/zinc paper is scored 8 (quality).

COI interpretive caution

COI evidence is not proof of bias, but it is a known risk factor for selective emphasis. In your dataset, the skin health narrative review includes an equity/founding relationship disclosure, whereas other selected records state no conflicts or do not state COI.

Scientific contribution pattern (what the provided evidence supports)

Strong thematic coherence around mitochondrial biology. Across selected records, mitochondrial dysfunction is linked to aging-like phenotypes (wrinkling/hair loss in a mtDNA depletion mouse model) and to mitochondrial–nucleus retrograde signaling (miR-663 epigenetically regulated by mitochondrial dysfunction/ROS and impacting OXPHOS architecture and tumor progression).
Mechanistic breadth: epigenetic regulation and metabolic rewiring. The miR-663 work (epigenetics + mitochondria–nucleus signaling + OXPHOS supercomplexes) complements older metabolic/mitochondrial enzyme regulation evidence in prostate tissues where mitochondrial aconitase is argued to be similarly abundant across benign/malignant contexts, while zinc/ZIP1 regulation is proposed as a driver of metabolic transformation.
Translation-intent is present but evidence strength varies by study type. The skin health record is a narrative review synthesizing cell/ex vivo/animal literature and discusses mitochondrial-targeted strategies (e.g., CoQ10, melatonin, NAM), but narrative reviews inherently carry selection-bias and heterogeneity concerns, and the record itself emphasizes reliance on preclinical/correlative findings.

Skeptical critique: where the evidence is strong vs uncertain

Reversibility claims (mtDNA depletion rescue) are compelling but not fully general. The provided record describes reversal of skin pathology after mtDNA repletion in a specific inducible mouse model, but the record also flags limitations: mouse-to-human translation uncertainty, doxycycline-related off-target effects as a potential confound, and lack of direct demonstration of downstream epigenetic causality.
miRNA/epigenetic mechanisms can be sensitive to experimental context. The miR-663 record uses cell lines and immunocompromised mouse xenografts, and the record notes off-target/non-physiological concerns typical of overexpression/knockdown and that TCGA correlations require prospective/independent validation. These are not “weaknesses” per se, but they bound confidence.
Prostate metabolic mechanism evidence is limited by sample size and measurement modality. The prostate record (2006) uses human tissues (small n≈22 cases), relies on semi-quantitative immunohistochemistry scoring, and—per the record—does not provide direct functional enzyme activity comparisons in tissue-level contexts, making it more hypothesis-generating than definitive.
Narrative review evidence is bounded: synthesis ≠ new experimental proof. The skin record is useful for mapping hypotheses/lines of evidence, but as a narrative review, it may reflect selection bias and inherits heterogeneity across included models. The record itself notes limited direct clinical data.

Evidence-based, content-anchored “bio profile” (from the provided records)

Core strengths: mitochondria-centered mechanistic framing; ability to connect mtDNA/mitochondrial dysfunction to tissue phenotypes; and use of multi-layer assays (e.g., OXPHOS supercomplex-related analyses and epigenetic regulation in the miR-663 chain; histology/inflammation/mitochondrial restoration in the mtDNA depletion rescue record).

Blind spots / confidence limits (from provided record fields): translational uncertainty (mouse ↔ humans), potential model/context dependence of miRNA perturbation effects, reliance on correlational clinical datasets (TCGA) for survival linkage, narrative-review selection bias, and measurement limits (small n and semi-quantitative scoring in the prostate record).

Index caveat

This index is my explicitly heuristic aggregation based on the limitation statements included in your dataset for each record; it is not a substitute for a full systematic review.

What would disprove or change these impressions?

If the mtDNA restoration “reversal” does not replicate across independent labs or if doxycycline/off-target effects fully explain some of the observed reversal markers, confidence in causality would drop.
If miR-663 effects on tumor phenotypes disappear when using more physiological delivery/levels, or if the epigenetic methylation link is not reproducible, the causal chain connecting mitochondria → ROS/DNA methylation → miR-663 → OXPHOS architecture would weaken.
If the prostate metabolic mechanism fails under larger cohorts or with more direct functional aconitase activity assays in tissue compartments, the zinc/ZIP1-driven switch would be less persuasive.

Next-step (optional BGPT deepening)

If you want a broader author-level review (beyond these 4 provided records), we should query BGPT for other full-text records by Keshav K. Singh specifically tagged to: mitochondria–nucleus retrograde signaling, mtDNA depletion models, and mitochondrial-targeting strategies.

Feedback:

Updated: March 23, 2026